Compare iShares MSCI Taiwan ETF (EWT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares MSCI Taiwan ETF trades at $114.31 (market cap $12.74B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| EWT | ZBH | |
|---|---|---|
Market Cap | $12.74B | $16.95B |
Volume | 8,470,920 | 2,505,240 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $103.98 |
52-Week Low | $60.03 | $79.58 |
Typical Hold Time | 52 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT trades at $114.31, down 1.66% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong exposure to Taiwan's semiconductor sector, particularly TSMC, driving AI-related growth potential. Recent news highlights Taiwan's $20 billion investment in US AI infrastructure and institutional buying interest from Bank of America.
Outlook remains positive due to Taiwan's central role in AI chip manufacturing, though geopolitical risks with China pose significant headwinds. Valuation appears reasonable for tech-focused exposure, but investors must weigh growth potential against regional political uncertainty.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
